[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363908-105":59,"doc-detail-363908-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","onco-nephrology-in-kidney-transplant-recipients-challenges-and-evolving-strategies","Onco-nephrology in kidney transplant recipients - challenges and evolving strategies","","Onco-nephrology in kidney transplant recipients examines how cancer risk emerges and evolves across the full transplant pathway. The review connects pretransplant donor and candidate assessment, post-transplant surveillance, and the consequences of immunosuppressive therapy for long-term malignancy development. It also addresses clinical decision-making after cancer diagnosis, focusing on the modulation of immunosuppression and coordination between nephrology and oncology. Special attention is given to new evidence on immune-checkpoint inhibitor treatment.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/onco-nephrology-in-kidney-transplant-recipients-challenges-and-evolving-strategies/363908/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/onco-nephrology-in-kidney-transplant-recipients-challenges-and-evolving-strategies/363908.png","ImageObject",300,407,{"name":92,"@type":93},"awa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What challenges does cancer create for kidney transplant recipients?","Question",{"text":112,"@type":113},"Cancer increases both short- and long-term morbidity and mortality in kidney transplant recipients, with risk shaped by the transplant process and ongoing care.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does immunosuppression affect cancer development after kidney transplantation?",{"text":117,"@type":113},"Immunosuppressive therapies needed to maintain renal function can contribute to the potential development of cancer, and complications—especially infectious ones—are implicated in long-term risk.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the clinical approach when cancer is diagnosed in a kidney transplant recipient?",{"text":121,"@type":113},"Nephrologists and transplant specialists must modulate immunosuppressive therapy, while collaborating with oncologists to manage specific cancer treatment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363908,1790797060,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","TYPE Review  \nPUBLISHED 14 July 2026  \nDOI 10.3389/fimmu.2026.1778752  \nOPEN ACCESS  \nEDITED BY  \nAntoine Toubert,  \nUniversite´ Paris Cite´, France  \nREVIEWED BY  \nChaiyaporn Boonchalermvichian, Indiana University Bloomington, United States  \nTess Van Meerhaeghe,  \nUniversite´ Libre de Bruxelles, Belgium  \n*CORRESPONDENCE  \nCarlo Alﬁeri  \n [carlo.al](carlo.al)ﬁ[eri1@gmail.com](eri1@gmail.com);  \n [carlo.al](carlo.al)ﬁ[eri@unimi.it](eri@unimi.it)[ ](eri@unimi.it)RECEIVED 31 December 2025 REVISED 01 April 2026 ACCEPTED 22 May 2026 PUBLISHED 14 July 2026  \nCITATION  \nAlﬁeri C, Simeoni M, Di Naro M, Mattinzoli D, Ikehata M, Armelloni S, Molinari P, Maggi M, Mella A, Regalia A, Verdesca S, Favi E, Cosmai L, Messa P and Castellano G (2026) Onconephrology in kidney transplant recipients: challenges and evolving strategies.  \nFront. Immunol. 17:1778752 .  \ndoi: 10.3389/fimmu.2026.1778752  \nCOPYRIGHT  \n© 2026 Alﬁeri, Simeoni, Di Naro, Mattinzoli, Ikehata, Armelloni, Molinari, Maggi, Mella, Regalia, Verdesca, Favi, Cosmai, Messa and Castellano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nOnco-nephrology in kidney transplant recipients: challengesand evolving strategies  \nCarlo Alﬁeri1,2*, Mariadelina Simeoni 3, Margherita Di Naro 1, Deborah Mattinzoli 4, Masami Ikehata 4, Silvia Armelloni 4, Paolo Molinari 1,2, Marco Maggi 1, Alberto Mella 5, Anna Regalia 1, Simona Verdesca 1, Evaldo Favi 2,6, Laura Cosmai 7,  \nPiergiorgio Messa 1 and Giuseppe Castellano 1,2  \n1 Unit of Nephrology, Dialysis and Kidney Transplantation, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, 2 Department of Clinical Sciences and Community Health, Dipartimento di Eccellenza, University of Milan, Milan, Italy, 3 Department of Translation Medical Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy, 4 Renal Research Laboratory, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, 5 Division of Nephrology Dialysis and Renal Transplantation- “Città della Salute e della Scienza” University Hospital, Turin, Italy, 6General Surgery and Kidney Transplantation, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, 7 UOC Nephrology and Dialysis, Azienda Socio-Sanitaria Territoriale (ASST) Fatebenefratelli-Sacco, Fatebenefratelli Hospital, Milan, Italy  \nCancer is a signiﬁcant cause of mortality in kidney transplant recipients (KTr) . Speciﬁcally, the relationship between cancer and kidney transplantation (KTx) is evident from the initial evaluation of CKD patients prior to their placement on the KTx waiting list. After KTx, a signiﬁcant impact on the potential development of cancer is linked to immunosuppressive therapies, necessary to maintain renal function post-KTx, and to complications, especially infectious ones, typical of these patients. Ultimately, once cancer is diagnosed in a KTx, nephrologists and transplant specialists are forced to modulate suppressive therapies and, together with oncologists, manage speciﬁc cancer treatment therapies. In this highly complex scenario, unfortunately, there are few certainties, and they are limited to a few studies, often involving a small number of patients. This review integrates current data on risk, prevention, and treatment across the entire pathway: pretransplant assessment, post-transplant surveillance, and management after a cancer diagnosis. A special focus will be reserved to the new evidences regarding the treatment with immune-checkpoint inhibitors (ICIs) .  \nKEYWORDS  \ncancer, immune checkpoint inhibitors, kidney transplant, mana","cbCaiu4ySS6z2XtZ","https://ap.wps.com/l/cbCaiu4ySS6z2XtZ","pdf",501352,"English","# Introduction\n# Cancer risk across the transplant pathway\n## Pretransplant assessment\n## Post-transplant surveillance and complications\n## Management after a cancer diagnosis\n# Focus on immune-checkpoint inhibitors","[{\"question\":\"What challenges does cancer create for kidney transplant recipients?\",\"answer\":\"Cancer increases both short- and long-term morbidity and mortality in kidney transplant recipients, with risk shaped by the transplant process and ongoing care.\"},{\"question\":\"How does immunosuppression affect cancer development after kidney transplantation?\",\"answer\":\"Immunosuppressive therapies needed to maintain renal function can contribute to the potential development of cancer, and complications—especially infectious ones—are implicated in long-term risk.\"},{\"question\":\"What is the clinical approach when cancer is diagnosed in a kidney transplant recipient?\",\"answer\":\"Nephrologists and transplant specialists must modulate immunosuppressive therapy, while collaborating with oncologists to manage specific cancer treatment.\"}]","Onco-nephrology in kidney transplant recipients - challenges and evolving strategies | PDF",1790154169,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/980d1e581264e3c82f58b9b5f02936fb.webp",983,1389,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9cf37e27c4388625a9710c2346f28a65.webp",982,1388,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61465d81080d01bb3ea4463f675560f2.webp",981,1386,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/16d6abe5b6748c3195b0c2908c4deb98.webp",980,1385]